随着新管理层上任、华熙生物入股，圣诺医药重新启航，依托自主研发的肽纳米颗粒（PNP）与GalAhead两大核心技术平台，聚焦肿瘤治疗、医美减脂、代谢性疾病等领域，探索精准RNA（核糖核酸）医疗的未来。那么，团队如何让患者用上创新药呢？广州日报全媒体记者一行走进苏州，与圣诺医药集团研发副总裁、苏州研发总部总经理田伟伟博士聊聊小核酸的故事。 行业特点小核酸被视为第三代生物医药革命性技术 作为全程见证...
Source Link随着新管理层上任、华熙生物入股，圣诺医药重新启航，依托自主研发的肽纳米颗粒（PNP）与GalAhead两大核心技术平台，聚焦肿瘤治疗、医美减脂、代谢性疾病等领域，探索精准RNA（核糖核酸）医疗的未来。那么，团队如何让患者用上创新药呢？广州日报全媒体记者一行走进苏州，与圣诺医药集团研发副总裁、苏州研发总部总经理田伟伟博士聊聊小核酸的故事。 行业特点小核酸被视为第三代生物医药革命性技术 作为全程见证...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.